Compare · JANX vs NVO
JANX vs NVO
Side-by-side comparison of Janux Therapeutics Inc. (JANX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JANX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 224.7x JANX ($991.6M).
- Over the past year, JANX is down 37.7% and NVO is down 22.5% - NVO leads by 15.2 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for JANX).
- NVO has more recent analyst coverage (25 ratings vs 19 for JANX).
- Company
- Janux Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $16.26+2.68%
- $50.31-2.25%
- Market cap
- $991.6M
- $222.81B
- 1M return
- +18.77%
- +15.47%
- 1Y return
- -37.70%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 4
- Recent ratings
- 19
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest JANX
- President and CEO Campbell David Alan exercised 7,000 shares at a strike of $4.21, increasing direct ownership by 2% to 388,582 units (SEC Form 4)
- Janux Therapeutics Inc. filed SEC Form 8-K: Other Events
- Director Ra Capital Management, L.P. was granted 5,500 shares (SEC Form 4)
- Director Simson Jake was granted 5,500 shares (SEC Form 4)
- Director Hernday Natasha was granted 5,500 shares, increasing direct ownership by 55% to 15,481 units (SEC Form 4)
- Director Kung Winston was granted 5,500 shares, increasing direct ownership by 88% to 11,750 units (SEC Form 4)
- Director Capps Vickie L was granted 5,500 shares, increasing direct ownership by 7% to 79,598 units (SEC Form 4)
- Director Barrett Ronald W was granted 5,500 shares, increasing direct ownership by 88% to 11,750 units (SEC Form 4)
- Director Dobmeier Eric was granted 5,500 shares, increasing direct ownership by 55% to 15,481 units (SEC Form 4)
- Janux Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S